10x Genomics (NASDAQ:TXG) Stock Price Up 6.6% – What’s Next?

21 Oct 2026, 13:00 by Scott Moore · The Cerbat Gem

10x Genomics (NASDAQ:TXG – Get Free Report) was up 6.6% during mid-day trading on Wednesday. The company traded as high as $76.16 and last traded at $76.1640. Approximately 909,022 shares traded hands during trading, a decline of 70% from the average daily volume of 2,990,099 shares. The stock had previously closed at $71.46.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TXG. Morgan Stanley raised their price objective on 10x Genomics from $40.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Monday, October 12th. Stephens boosted their price target on shares of 10x Genomics from $50.00 to $65.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Argus initiated coverage on shares of 10x Genomics in a report on Monday, September 28th. They set a “buy” rating and a $110.00 target price on the stock. Piper Sandler increased their price objective on 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. Finally, Leerink Partners boosted their price objective on 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 29th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $68.00.

Read Our Latest Report on 10x Genomics

10x Genomics Stock Performance

The firm’s 50-day moving average is $71.59 and its 200 day moving average is $46.36. The stock has a market cap of $9.93 billion, a PE ratio of -129.40 and a beta of 1.99.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. The company’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. On average, sell-side analysts predict that 10x Genomics will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director John Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the sale, the director owned 328,436 shares of the company’s stock, valued at $20,280,923. The trade was a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Serge Saxonov sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the transaction, the chief executive officer directly owned 1,050,249 shares of the company’s stock, valued at approximately $85,301,223.78. This represents a 2.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 179,333 shares of company stock worth $11,810,070 in the last three months. 8.84% of the stock is currently owned by insiders.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently modified their holdings of the business. Sei Investments Co. lifted its stake in 10x Genomics by 113.5% in the first quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock valued at $949,000 after buying an additional 23,748 shares during the last quarter. Squarepoint Ops LLC acquired a new position in 10x Genomics during the 2nd quarter worth $2,069,000. HB Wealth Management LLC acquired a new position in 10x Genomics during the 2nd quarter worth $285,000. Proficio Capital Partners LLC acquired a new position in shares of 10x Genomics during the second quarter valued at $781,000. Finally, Hsbc Holdings PLC acquired a new stake in 10x Genomics in the first quarter worth about $5,945,000. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.